Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer In Vitro

CHIASA HIRAKAWA, KUNIHIKO TANAKA, YOSHIHIRO TAKAYA, SHINSUKE NAKAGAWA, YASUFUMI KATAOKA, YUTAKA TAGAWA and MASAMI NIWA
Anticancer Research July 2009, 29 (7) 2541-2545;
CHIASA HIRAKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KUNIHIKO TANAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kunny-ta{at}net.nagasaki-u.ac.jp
YOSHIHIRO TAKAYA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINSUKE NAKAGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUFUMI KATAOKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTAKA TAGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAMI NIWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Metastasis is a leading cause of cancer death. To evaluate the complex metastatic process in vitro, an attempt was made to develop a cell-based assay (Can kit) that could evaluate the late stages of metastasis. Materials and Methods: Two membrane chambers were set up of which the upper membrane chamber with 8 μm pores was covered with normal cell layers. Cancer cells were introduced to the upper chamber and after passing through the normal cell layers dropped through onto the lower chamber membrane where cancer colonies formed and were evaluated based on the reduction of transepithelial electrical resistance (TEER) with a Madin-Darby canine kidney (MDCK) cell monolayer. Results: When two pairs of cancer cell lines, with different metastatic potentials in vivo, were applied to the Can kit assay, differences in potentials between the two cell lines in vitro were demonstrated. The reduction in the TEER was correlated with the total area of the cancer colonies and the production of matrix metalloproteinases (MMPs). Conclusion: A cell-based assay able to evaluate the malignant potential of cancer in vitro was developed and is considered to be useful for research and the clinical examination of cancer metastatic potential.

  • Cancer
  • metastasis
  • malignant potential
  • cell-based assay
  • anoikis
  • matrix metalloproteinase (MMP)

Metastases, rather than primary tumors, are responsible for approximately 90% of all cancer deaths (1, 2). The metastatic process consists of a series of complex stages (3-5). When the diameter of a primary tumor exceeds 1-2 mm, it needs to develop a blood supply that can support its growth and metabolism (6). This process is called angiogenesis. The new blood vessels also provide an escape route through which cancer cells detach from the primary tumor and enter the circulation, a process known as intravasation. Ultimately, most circulating cancer cells die owing to anoikis. However, surviving cancer cells can arrest in the capillary vessels of distant organs, adhere to the endothelial cells and extravasate into the surrounding tissue. If the cancer cells adapt to the microenvironment in the secondary sites, they grow and form a metastatic nodule.

The comprehensive evaluation of the metastatic potential of cancer is difficult because of the complex metastatic process. A number of researchers have studied this process using inoculation of cancer cells into immunodeficient mice to investigate the metastatic process because this represents the whole process of metastasis. However, attempts to study this process in vivo have presented some difficulties in terms of orthotopic grafts in mice and the continuous observation of cancer cells. Furthermore, long periods of time are needed to obtain a result. On the other hand, a few in vitro assays have been used to evaluate the malignant potential of cancer. Each in vitro assay can generally only evaluate one stage of metastasis. For example, the Matrigel invasion assay can evaluate only the potential for invasion, even though the assay involves adhesion to the extracellular matrix, proteolysis and chemotactic migration (7). Therefore, the development of an in vitro assay that can accurately determine the malignant potential of cancer, particularly the metastatic potential, is required to advance cancer research and help to reduce the number of cancer deaths.

In this study, a new cell-based assay (Can kit) was developed to reconstruct the latter stages of metastasis in vitro, which include the adhesion of cancer cells to endothelial cells, extravasation, and growth of the metastatic nodule. The mechanism of the reduction of transepithelial electrical resistance (TEER) was also investigated using the colony formation of cancer cells and the expression of matrix metalloproteinase (MMP) -2 and -9 in the Can kit.

Materials and Methods

Cell culture. NIH3T3 (murine embryonic fibroblast cell line) was purchased from RIKEN BioResorce Center (Tsukuba, Ibaragi, Japan). GP8.3 (rat brain endothelial cell line) was a gift from Dr. Maria A. Deli. MDCK NBL-2 (Madin-Darby canine kidney cell line), B16-F0 and B16-F10 (murine malignant melanoma cell lines) and SW480 and SW620 (human colon cancer cell lines) cells were purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), 100 units/ml penicillin, 100 μg/ml streptomycin (Gibco BRL, Rockville, MD, USA) and 10 μg/ml Mycokill AB (PAA Laboratories GmbH, Pasching, Austria). The cells were used for experiments within 10 passages. All the cell lines were grown in a humidified incubator with 95% air, 5% CO2 at 37°C. The two pairs of cancer cell lines have known different malignant potentials in vivo. The B16-F0 cells have low metastatic potential and the B16-F10 cells have high metastatic potential, and the SW480 cells have no metastatic potential and the SW620 cells have high metastatic potential in vivo.

Can kit protocol. The Can kit comprised two membrane chambers, a 12-well plate and NIH3T3, GP8.3 and MDCK cells. The upper chamber contained a Chemotaxicell filter with 8 μm pores (Kurabo, Osaka, Japan) and the lower chamber was a 12-well Transwell with 0.4 μm pores (#3460; Corning Inc., Lowell, MA, USA) through which cells could not pass. On day 1, 2.4-2.5×105 NIH3T3 fibroblast cells were plated and cultured on the reverse side of the membrane of the upper chamber. After 6 hours, the upper chamber was set in a 24-well plate and cultured for 2 days. The NIH3T3 cells were used as the feeder layer for the GP8.3 endothelial cells and the cancer cells, and as the physiological barrier against the migration of the GP8.3 cells. A total of 1.7-3.0×105 GP8.3 cells were seeded on the observation side of the membrane in the upper chamber and cultured. Thus, the upper chamber was equivalent to a blood vessel and the environment below the upper chamber was equivalent to a metastatic site.

After cultivation for 1 day, 2.5-3.0×105 cancer cells were seeded in the upper chamber and it was placed on the lower chamber in a 12-well plate. The next day, the upper chamber was removed and the cells that had dropped through into the lower chamber were further cultured for 2 days. Then 2.0×105 MDCK cells were seeded in the lower chamber, and the TEER was measured after 7-16 days (Figure 1).

TEER measurement. TEER was measured with a planar electrode chamber, which was connected to an EVOM Epithelial Voltohmmeter (World Precision Instruments, Berlin, Germany). The background resistance (Transwell without cells) was subtracted from the resistance of the samples. TEER of the MDCK monolayer exceeding 6,000 Ω·cm2 was considered to represent an intact epithelium. Samples without seeding of cancer cells in the upper chamber were used as controls. At least two independent experiments were conducted for each cell line.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Protocol of the cell-based assay (Can kit). NIH3T3 cells are cultured on the reverse side of the upper chamber membrane with 8 μm pores. After 2 days, GP8.3 cells are cultured on the membrane. The next day, cancer cells are plated in the upper chamber and the double chamber was placed in a 12-well plate. Some cancer cells penetrate the upper chamber membrane, covered with the normal cell layers, and drop onto the lower chamber membrane. The next day, the upper chamber is removed and MDCK cells are plated on the lower chamber membrane 2 days later. After the MDCK cells form a complete monolayer with the cancer colonies, the TEER (transepithelial electrical resistance) is measured.

Colony evaluation. Cancer cell colony formation on the lower chamber membrane was assessed after the TEER was measured. The total area of cancer colonies per well was estimated under an inverted microscope at ×100.

Gelatin zymography. Gelatin zymography was performed as described in the manufacturer's protocol (Millipore, Billerica, MA, USA). In brief, the conditioned medium in the lower chamber of the Can kit was changed to 100 μl of serum-free medium after the TEER measurement and colony evaluation. After culture for 1 day, 15 μl of the conditioned medium was mixed with 5 μl of sample buffer (0.5 M Tris-HCl, pH 6.8, 40% glycerol, 0.01% bromophenol blue and 8% SDS) and then incubated for 10 min at room temperature. The samples were electrophoresed on a 10% SDS-polyacrylamide gel containing 1 mg/ml gelatin (Nacalai Tesque, Kyoto, Japan). After electrophoresis, the gel was incubated in 2.5% Triton® X-100 for 30 min, washed in the developing buffer (0.05 M Tris-HCl, 0.2 M NaCl, 5 mM CaCl2, and 1 μM ZnCl2) for 30 min and incubated at 37°C overnight. The gel was stained with 0.5% Coomassie brilliant blue R250 for 30 min and destained with 50% methanol and 10% acetic acid in water. The clear bands resulting from digestion of the substrate by gelatinase were then visualized.

Statistical analysis. All the experiments were performed at least in triplicate. Student's t-test was used to compare the means of the groups. A p-value of <0.05 was considered to indicate a statistically significant difference.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

TEER measurements of two pairs of cancer cell lines (A) B16-F0 and B16-F10 and (B) SW480 and SW620. TEER (ohms·cm2; ohms × surface area) was calculated by subtracting the resistance of a cell-free lower chamber membrane and correcting for surface area. Values are means±SE (n=3). *p<0.05.

Results

TEER measurements. As shown in Figure 2A, both the B16-F0 and B16-F10 cells significantly reduced the TEER compared with the controls (control: 6040±590 Ω·cm2; B16-F0: 4273±625 Ω·cm2; B16-F10: 829±432 Ω·cm2). The B16-F10 cells showed a more significant reduction in the TEER than did the B16-F0 cells.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Cancer colonies on the lower chamber membrane of the Can kit observed under an inverted microscope. (A) MDCK cells plated on the new lower chamber membrane without the other cells; (B) Control in which cancer cells were not seeded on the upper chamber of the Can kit; (C) B16-F0; (D) B16-F10; (E) SW480 and (F) SW620 cells. Original magnification ×100.

The SW620 cells significantly reduced the TEER, whereas the SW480 cells did not cause a significant reduction in TEER compared with the control cells (control: 6433±159 Ω·cm2; SW480: 5753±202 Ω·cm2; SW620: 2350±278 Ω·cm2; Figure 2B). There was also a significant difference in the TEER between the SW480 and the SW620 cells.

Colony evaluations. To clarify the mechanism by which the TEER is reduced by the presence of the cancer cells, the cancer cell colony formation and area on the membrane of the lower chamber were evaluated. Compared with the MDCK monolayer (Figure 3A), even the control samples showed round colonies (Figure 3B) and they were considered to be GP8.3 cells or NIH3T3 cells because cancer cells were not seeded in the control tests. The B16-F0 cells formed round colonies with lateral branches (Figure 3C), whereas the B16-F10 cells formed ameba-like colonies with lateral branches (Figure 3D). The total area occupied by the colonies of B16-F10 was four times larger than that of B16-F0. The SW480 cells formed round colonies (Figure 3E) while the SW620 cells formed oval colonies with long lateral branches (Figure 3F). The total area occupied by the colonies of SW620 was three times larger than that of SW480.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Gelatin zymography of the conditioned media from the Can kit. Conditioned media in the lower chamber was electrophoresed on 10% SDS-PAGE containing 1 mg/ml gelatin. Clear bands resulting from digestion by gelatinase were visualized by Coomassie staining. The left and middle pictures are from the same gel at the same time.

Gelatin zymography. MMP-2 and MMP-9 were detected in the conditioned medium from the control sample. MMP-9 activity was detected in the conditioned medium from the MDCK cells, but the MMP-2 activity was much lower (Figure 4, left). The activity of MMP-9 in the conditioned media from the B16-F0 and B16-F10 samples was less than that of the control sample. The activity of MMP-2 in the conditioned medium from the B16-F10 sample was greater compared with that in the control and B16-F0 samples (Figure 4, middle). Although the MMP-9 activity in the conditioned medium from the SW480 sample was slightly greater than those of the control and the SW620 samples, MMP-2 activity in the conditioned medium from the SW620 sample was greater compared with that in the control and SW480 samples (Figure 4, right).

Discussion

In the present study, some of the disseminated cancer cells with high malignant potential adhered to the endothelial cells, invaded the layer of endothelial cells and fibroblast cells passing through the 8 μm pores, and then dropped into the lower chamber. A few endothelial cells and fibroblast cells also dropped into the lower chamber. We have previously reported that some of the cancer cells that drop from the membrane can survive (8). It has also been reported that the dropped cancer cells are more malignant than the parent cells (9, 10). Observations of the cancer colonies suggested that the colonizing abilities in the Can kit were correlated with the malignant potential of the cancer. When the TEER was measured at the end of the culture period, many cancer cells were dead and floating in the lower chamber (data not shown). Penetration through the normal cell layers and the membrane pores, and dropping into the medium was most probably a difficult process for the cancer cells, and only those with high malignant potential and resistance to anoikis could form substantial colonies on the lower chamber membrane.

The TEER of the total cells on the lower chamber membrane was measured when the MDCK cells had formed a complete monolayer. MDCK cells have been reported to have a high TEER when they form a monolayer because their tight junctions are very rigid (11). The results of an electrical resistance breakdown assay in which cancer cells induced breakdown of the TEER when they were co-cultured with a MDCK monolayer were previously reported (12, 13). This principle was applied in the Can kit.

The murine malignant melanoma cell line B16-F10 was established by repeated injection of tumor cells into nude mice and recovering the cells from pulmonary tumor nodules in vivo (14). It has been reported that B16-F10 is more metastatic compared with the parental cell line B16-F0 in pulmonary colonization (15). When these two cell lines were tested with the Can kit, both cell lines showed malignant potential, but the B16-F10 cells were more malignant than the B16-F0 cells based on the magnitude of the TEER reduction. The present data were thus consistent with the data of the metastatic potential in vivo of these cell lines. Interestingly, Gehlsen et al. described that, of the B16 cell lines selected for variant metastatic behavior in vivo, B16-F1 and B16-F10 had similar invasion profiles on an invasion assay in vitro (16). Therefore the present assay was able to evaluate the strength of the malignant potential of these cancer cells, which the invasion assays could not determine.

The human colon cancer cell lines SW480 and SW620 were respectively derived from a primary tumor and lymph node metastasis resected from a single patient (17). It has been reported that when these two cell lines were inoculated into nude mice, the SW480 cells did not form a secondary tumor in the liver (no metastatic potential), but the SW620 cells did (high metastatic potential) (18, 19). When SW480 and SW620 cells were evaluated using the Can kit, the SW620 cells significantly reduced the TEER, but the SW480 cells did not. These data were therefore also consistent with the in vivo data. Although many researchers have reported that SW620 cells are more invasive than SW480 based on the results of invasion assays (20-22), Kusakai et al. showed the opposite results using the Matrigel invasion assay (23). The studies indicate that the invasion assays are influenced by the experimental conditions and that appropriate experimental conditions were used in the Can kit.

MMPs are known to play a crucial role in cancer spread and invasion due to the degradation of the extracellular matrix and basal membrane. Gelatin zymography showed that MMPs, particularly MMP-2, were involved in the reduction of the TEER in the Can kit. When the SW480 and SW620 cells were evaluated without NIH3T3, the MMP-2 activities of both cell lines were barely detectable (data not shown). Che et al. reported that the MMP-2 activity of oral squamous carcinoma cells was increased when they were co-cultured with fibroblast cells (24). The data suggested that the fibroblast cells played an important role not only as the feeder layer, but also as a microenvironment for the cancer cells in the Can kit.

In conclusion, a novel cell-based assay has been developed that can evaluate the late stages of metastasis in vitro. In this assay, the reduction of the TEER was correlated with the area occupied by the cancer colonies and with MMP production in the lower chamber. The present assay is easy to handle and requires less time compared with in vivo experiments. Therefore, we believe the Can kit will be useful for a range of applications both in research and clinical settings.

Acknowledgements

This study was supported in part by a grant from the New Industry Creative-Type Technology R&D Promotion Programs from the Ministry of Economy, Trade and Industry (2005, 2006).

Footnotes

  • ↵* Both authors contributed equally to this study.

  • Received January 30, 2009.
  • Revision received April 9, 2009.
  • Accepted April 27, 2009.
  • Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Christofori G
    : New signals from the invasive front. Nature 441: 444-450, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mehlen P,
    2. Puisieux A
    : Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458, 2006.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Chambers AF,
    2. Groom AC,
    3. MacDonald IC
    : Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
    OpenUrlCrossRefPubMed
    1. Bogenrieder T,
    2. Herlyn M
    : Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524-6536, 2003.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gupta GP,
    2. Massague J
    : Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Fidler IJ
    : The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hendrix MJ,
    2. Seftor EA,
    3. Seftor RE,
    4. Fidler IJ
    : A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38: 137-147, 1987.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Takaya Y,
    2. Tanaka K,
    3. Hirakawa C,
    4. Tagawa Y,
    5. Niwa M
    : New method for separation of subpopulations from a heterogeneous colon cancer cell line. Anticancer Res 28: 3665-3670, 2008.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Okada T,
    2. Li J,
    3. Kodaka M,
    4. Okuno H
    : Enhancement of type IV collagenases by highly metastatic variants of HT1080 fibrosarcoma cells established by a transendothelial invasion system in vitro. Clin Exp Metastasis 16: 267-274, 1998.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kao WT,
    2. Lin CY,
    3. Lee LT,
    4. Lee PPH,
    5. Hung CC,
    6. Lin YS,
    7. Chen SH,
    8. Ke FC,
    9. Hwang JJ,
    10. Lee MT
    : Investigation of MMP-2 and -9 in a highly invasive A431 tumor cell sub-line selected from a Boyden chamber assay. Anticancer Res 28: 2109-2120, 2008.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Furuse M,
    2. Furuse K,
    3. Sasaki H,
    4. Tsukita S
    : Conversion of zonulae occludentes from tight to leaky strand by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol 153: 263-272, 2001.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Zak J,
    2. Schneider SW,
    3. Eue I,
    4. Ludwig T,
    5. Oberleithner H
    : High-resistance MDCK-C7 monolayers used for measuring invasive potency of tumour cells. Pflugers Arch 440: 179-183, 2000.
    OpenUrlPubMed
  12. ↵
    1. Ludwig T,
    2. Ossig R,
    3. Graessel S,
    4. Wilhelmi M,
    5. Oberleithner H,
    6. Schneider SW
    : The electrical resistance breakdown assay determines the role of proteinases in tumor cell invasion. Am J Physiol Renal Physiol 283: 319-327, 2002.
    OpenUrl
  13. ↵
    1. Fidler IJ
    : Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35: 218-224, 1975.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Poste G,
    2. Doll J,
    3. Hart IR,
    4. Fidler IJ
    : In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40: 1636-1644, 1980.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Gehlsen KR,
    2. Hendrix MJ
    : In vitro assay demonstrates similar invasion profiles for B16F1 and B16F10 murine melanoma cells. Cancer lett 30: 207-212, 1986.
    OpenUrlPubMed
  16. ↵
    1. Leibovitz A,
    2. Stinson JC,
    3. McCombs WB,
    4. McCoy CE,
    5. Mazur KC,
    6. Marbry ND
    : Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569, 1976.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hewitt RE,
    2. McMarlin A,
    3. Kleiner D,
    4. Wersto R,
    5. Martin P,
    6. Tsoskas M,
    7. Stamp GW,
    8. Stetler-Stevenson WG
    : Validation of a model of colon cancer progression. J Pathol 192: 446-454, 2000.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Dawan P,
    2. Singh AB,
    3. Deane NG,
    4. No Y,
    5. Shiou SR,
    6. Schmidt C,
    7. Neff J,
    8. Washington MK,
    9. Beauchamp RD
    : Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115: 1765-1776, 2005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Witty JP,
    2. McDonnell S,
    3. Newell KJ,
    4. Cannon P,
    5. Navre M,
    6. Tressler RJ,
    7. Matrisian LM
    : Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54: 4805-4812, 1994.
    OpenUrlAbstract/FREE Full Text
    1. Cho CY,
    2. Wang JH,
    3. Chang HC,
    4. Chang CK,
    5. Hung WC
    : Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 213: 65-69, 2007.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Zhu XL,
    2. Liang L,
    3. Ding YQ
    : Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis 23: 1041-1047, 2008.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kusakai G,
    2. Suzuki A,
    3. Ogura T,
    4. Miyamoto S,
    5. Ochiai A,
    6. Kaminishi M,
    7. Esumi H
    : ARK5 expression in colorectal cancer and its implications for tumor progression. Am J Pathol 164: 987-995, 2004.
    OpenUrlPubMed
  22. ↵
    1. Che ZM,
    2. Jung TH,
    3. Choi JH,
    4. Yoon DJ,
    5. Jeong HJ,
    6. Lee EJ,
    7. Kim J
    : Collagen-based co-culture for invasive study on cancer cells-fibroblasts interaction. Biochem Biophys Res Commun 346: 268-275, 2006.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 29, Issue 7
July 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer In Vitro
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer In Vitro
CHIASA HIRAKAWA, KUNIHIKO TANAKA, YOSHIHIRO TAKAYA, SHINSUKE NAKAGAWA, YASUFUMI KATAOKA, YUTAKA TAGAWA, MASAMI NIWA
Anticancer Research Jul 2009, 29 (7) 2541-2545;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Development of a Novel Cell-based Assay to Evaluate the Malignant Potential of Cancer In Vitro
CHIASA HIRAKAWA, KUNIHIKO TANAKA, YOSHIHIRO TAKAYA, SHINSUKE NAKAGAWA, YASUFUMI KATAOKA, YUTAKA TAGAWA, MASAMI NIWA
Anticancer Research Jul 2009, 29 (7) 2541-2545;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Coumarin-based Oximes Exert Monoamine Oxidase Inhibitory Activity
  • Selective Inhibition of Protein Kinase D2 Activity Reduces Human Neutrophil Survival
  • POM121 Drives Gastric Cancer Progression via the mTOR/p70S6K Signaling Axis
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire